FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 354 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Using Technology to Find Cancers Early and Exercise Improves Sexual Health... July 31, 2023 Immune cell count could determine whether chemotherapy is required in oropharyngeal... May 2, 2022 Tattoo Artist Helps Breast Cancer Survivors Cover Their Port Scars October 21, 2021 Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 Load more HOT NEWS A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability... Job Loss During Cancer: How to Cope and Continue Treatment Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom...
